[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368488-105":59,"doc-detail-368488-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prevalence-and-clinicopathological-features-of-human-epidermal-growth-factor-receptor-2low-breast-cancers-a-single-center-experience","Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers - A single-center experience","","Human epidermal growth factor receptor-2–low breast cancer, defined by low-level HER-2 expression and an immunohistochemistry score of 1+ or 2+ without amplification, has been proposed as a distinct subgroup. This retrospective single-center study assessed prevalence and clinicopathological characteristics of invasive breast carcinoma cases from 2021 to 2023. HER-2–low accounted for 54.7%, with predominantly grade 2 tumors, mean patient age around 60 years, and lower Ki-67 than other HER-2 groups, while axillary lymph node metastasis rates were similar.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-and-clinicopathological-features-of-human-epidermal-growth-factor-receptor-2low-breast-cancers-a-single-center-experience/368488/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-and-clinicopathological-features-of-human-epidermal-growth-factor-receptor-2low-breast-cancers-a-single-center-experience/368488.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How is HER-2–low breast cancer defined in the study?","Question",{"text":112,"@type":113},"It is characterized by low-level HER-2 expression with an immunohistochemistry (IHC) score of 1+ or 2+ without amplification.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was the prevalence of HER-2–low among included patients?",{"text":117,"@type":113},"Among 181 patients, 54.7% were classified as HER-2–low.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinicopathological differences were observed between HER-2–low and other groups?",{"text":121,"@type":113},"HER-2–low tumors were mainly grade 2, had a mean patient age around 60 years, and showed significantly lower Ki-67 proliferation rates; axillary lymph node metastasis rates did not differ significantly.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368488,1790647460,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience  \nılkay Cinar   \nJournal of International Medical Research 2025, Vol. 53(5) 1–10! The Author(s) 2025 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/03000605251342508](DOI: 10.1177/03000605251342508)[ ](DOI: 10.1177/03000605251342508)[journals.sagepub.com/home/imr](journals.sagepub.com/home/imr)  \nAbstract  \nObjective: Human epidermal growth factor receptor-2–low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1 þ or immunohistochemistry score 2þ without amplification, has been proposed as a distinct subgroup. This study investigated the prevalence and clinicopathological characteristics of human epidermal growth factor receptor-2–low breast cancers.  \nMethods: A retrospective observational cohort study was conducted on patients diagnosed with invasive breast carcinoma between 2021 and 2023 at a single tertiary center. Data on histological type, tumor grade, human epidermal growth factor receptor-2 status, and Ki-67 proliferation index were collected.  \nResults: Among the 181 patients who were included, 54.7% were classified as human epidermal growth factor receptor-2–low, 27.6% as human epidermal growth factor receptor-2–negative, and 17.7% as human epidermal growth factor receptor-2–positive. Human epidermal growth factor receptor-2–low tumors were predominantly those classified into grade 2 (69.7%). The mean age of patients with human epidermal growth factor receptor-2–low tumors was 60 years. The Ki-67 index was significantly lower in human epidermal growth factor receptor-2–low tumors than inhuman epidermal growth factor receptor-2–positive and human epidermal growth factor receptor-2–negative groups (p ¼ 0.001). No significant differences were observed in the rates of axillary lymph node metastasis among the groups (p ¼ 0.13).  \nDepartment of Pathology, Faculty of Medicine, Giresun University, Trkiye  \nCorresponding author:  \nIlkay Cinar, Department of Pathology, Faculty of Medicine, Giresun University, Gazipaa Yerlekesi Debboy Mevki, Merkez-Giresun/Tu¨rkiye.  \nEmail: [a.ilkaycinar@gmail.com](a.ilkaycinar@gmail.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative  \nCommons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \nConclusion: Human epidermal growth factor receptor-2–low breast cancers constitute a significant proportion of breast cancer cases and are associated with distinct clinicopathological features, including high estrogen reception positivity and lower Ki-67 proliferation rates.  \nKeywords  \nHuman epidermal growth factor receptor-2–low, breast cancers, estrogen receptor, progesterone receptor, Ki-67 antigen  \nDate received: 4 February 2025; accepted: 29 April 2025  \nIntroduction  \nBreast cancer is the most commonly diagnosed malignancy in women and a leading cause of cancer-related death worldwide.1 Human epidermal growth factor receptor 2 (HER-2) plays an important role in the biology of breast cancer. HER-2 gene amplification is associated with a poorer prognosis and a more aggressive disease course.2 Furthermore, it is critical for determining targeted treatment options. HER-2 status in breast cancer is routinely assessed and reported in pathology reports. Guidelines published by the American Society of Clinical Oncology/College of American Pathologists (ASC","cbCaimAabq0NOWGA","https://ap.wps.com/l/cbCaimAabq0NOWGA","pdf",744248,"English","# Abstract\n# Objective\n# Methods\n# Results\n# Conclusion\n# Keywords\n# Introduction\n# Methods","[{\"question\":\"How is HER-2–low breast cancer defined in the study?\",\"answer\":\"It is characterized by low-level HER-2 expression with an immunohistochemistry (IHC) score of 1+ or 2+ without amplification.\"},{\"question\":\"What was the prevalence of HER-2–low among included patients?\",\"answer\":\"Among 181 patients, 54.7% were classified as HER-2–low.\"},{\"question\":\"What clinicopathological differences were observed between HER-2–low and other groups?\",\"answer\":\"HER-2–low tumors were mainly grade 2, had a mean patient age around 60 years, and showed significantly lower Ki-67 proliferation rates; axillary lymph node metastasis rates did not differ significantly.\"}]","Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers - A single-center experience | PDF",1790177212,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73eeefeb21be84615ea14b89f81a69c0.webp",983,1399,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55376a15630c5b7d747582c434d1b742.webp",982,1398,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc93a6087d2b5ac75487c14f6f1ec6f3.webp",981,1396,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb13071cf8501b1d3ab27a3628599e7d.webp",980,1395]